Onco-Innovations Advances DNA Damage Response Therapies and AI-Driven Precision Oncology

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H), a clinical-stage oncology company, is advancing a new class of DNA Damage Response (DDR) therapies and developing artificial intelligence-driven precision oncology solutions. The company focuses on Polynucleotide Kinase Phosphatase (PNKP) inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance.

Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation. This strategy aims to address critical challenges in oncology, such as treatment resistance and tumor heterogeneity, by leveraging computational tools to identify biomarkers and optimize patient selection.

The company has secured an exclusive worldwide license to patented technology targeting solid tumors. Onco-Innovations is dedicated to pursuing the prevention and treatment of cancer through pioneering research and innovative solutions. For more information, visit the company’s website at https://oncoinnovations.com.

This announcement is significant as it underscores the growing importance of DDR inhibitors in oncology. By targeting PNKP, Onco-Innovations aims to disrupt DNA repair mechanisms that cancer cells rely on for survival, potentially enhancing the efficacy of existing treatments like chemotherapy and radiation. Combined with AI-driven precision medicine, the company’s approach could lead to more personalized and effective cancer therapies.

The implications extend beyond drug development. Onco-Innovations’ AI tools may improve clinical trial design and accelerate the identification of patient subgroups that benefit most from specific therapies. This could reduce trial costs and timelines while increasing success rates. As the oncology field moves toward biomarker-driven treatments, companies like Onco-Innovations are well-positioned to contribute to the next generation of cancer care.

Investors and researchers are closely watching Onco-Innovations as it progresses its pipeline. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.